Supplemental Table 2.
Uni- and multivariate logistic regression analyses results for evaluating variables associated with breakthrough
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| Variables | OR | 95% CI | P | OR | 95% CI | P |
| Age | 0.904 | 0.847-0.966 | 0.003 | 0.904 | 0.840-0.973 | 0.007 |
| BMI | 1.315 | 1.095-1.578 | 0.003 | 1.328 | 1.076-1.639 | 0.008 |
| DM, yes | 0.311 | 0.039-2.468 | 0.269 | |||
| HTN, yes | 2.078 | 0.654-6.603 | 0.215 | |||
| Pre-biopsy PSA | 0.994 | 0.985-1.004 | 0.236 | |||
| Prostate volume | 0.970 | 0.931-1.011 | 0.147 | |||
| Biopsy Gleason Score | ||||||
| 6 | Reference | |||||
| 7 | 0.606 | 0.126-2.913 | 0.532 | |||
| ≥8 | 0.463 | 0.087-2.457 | 0.366 | |||
| Percent of positive core number | 0.995 | 0.979-1.010 | 0.482 | |||
| Clinical T stage | ||||||
| ≤2 | Reference | |||||
| ≥3 | 1.233 | 0.407-3.735 | 0.711 | |||
| Clinical N stage | ||||||
| N0 | Reference | |||||
| N1 | 1.129 | 0.371-3.432 | 0.831 | |||
| Clinical M stage | ||||||
| M0 | Reference | Reference | ||||
| M1 | 0.276 | 0.061-1.264 | 0.095 | 0.555 | 0.235-1.311 | 0.179 |
| Therapeutic regimen | ||||||
| LHRH agonist monotherapy | Reference | Reference | ||||
| CAB | 0.177 | 0.062-0.504 | 0.001 | 0.113 | 0.034-0.377 | <0.001 |
BMI: body mass index; CAB: complete androgen blockade; CI: confidence interval; DM: diabetes mellitus; HTN: hypertension; LHRH: luteinizing hormone-releasing hormone; OR: odd ratio; PSA: prostate-specific antigen